Last updated: February 25, 2026
What is NDC 00075-2915?
NDC 00075-2915 corresponds to a specific drug product listed in the National Drug Code (NDC) database. The product identified by this code is Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy used for spinal muscular atrophy (SMA) in pediatric patients.
Market Overview
Indication and Market Size
Zolgensma targets children under two years old diagnosed with SMA Type 1, a hereditary genetic disorder characterized by loss of motor neurons. SMA Type 1 is the most severe form with rapid progression.
Estimated US Market Size:
- Children under 2 with SMA: approximately 400-500 new cases annually.
- Total eligible population: roughly 2,000 patients in the US, considering global prevalence estimates.
- Market penetration is increasing as newborn screening for SMA expands.
Competitive Landscape
- Spinraza (nusinersen) by Biogen and Evrysdi (risdiplam) by Roche serve as primary competitors.
- Spinraza is administered via intrathecal injection, priced at ~$750,000 for the first year.
- Evrysdi is an oral therapy with a list price of ~$340,000 annually.
- Zolgensma's one-time intravenous infusion cost is approximately $2.1 million in the US.
Regulatory and Reimbursement Environment
- Approved by FDA (2019) under a unique gene therapy designation.
- CMS and private insurers cover Zolgensma with conditions, primarily for confirmed SMA Type 1 cases.
- Constraints include high upfront costs and variability in insurance coverage.
Price Projections and Revenue Potential
Current Pricing and Revenue
- List Price: $2.1 million per dose (single infusion).
- Pricing assumptions vary by region but remain stable in the US.
- Sales figures: Novartis reports annual sales of over $330 million for Zolgensma (2022), indicating adoption for less than 2000 US patients annually.
Future Price Trends
- Price stability: Likely to remain around $2.1 million due to lack of direct competitors offering a one-time cure.
- Potential discounts: Insurance negotiations and hospital procurement might lead to discounts of up to 10-15%, bringing effective prices to $1.8-$2 million.
Revenue Growth Outlook
| Year |
Estimated Patients |
Gross Revenue (USD millions) |
Assumptions |
| 2023 |
1,200 |
$2,520 |
Growth driven by increased diagnosis and expanded coverage |
| 2024 |
1,500 |
$3,150 |
Improved reimbursement landscape, expanded screening |
| 2025 |
1,700 |
$3,570 |
Further market penetration |
Market Expansion Opportunities
- Global markets: China, Europe, Japan show increasing approval and uptake.
- Broader indications: Potential expansion into older SMA patients or other genetic disorders, if supported by clinical data.
Competitive and Economic Considerations
- The high upfront cost of Zolgensma limits affordability, leading to pressure for discounts.
- Cost-effectiveness models (e.g., ICER reports) suggest that the high price is offset by the cost savings of a one-time curative gene therapy versus ongoing treatments.
- Price negotiations may influence future pricing strategies, including potential tiered pricing or outcomes-based arrangements.
Key Risks and Challenges
- Reimbursement policies could tighten, reducing net revenue.
- Emergence of alternative gene therapies or biosimilars could erode market share.
- Clinical development delays or regulatory actions affecting approvals in other markets.
Key Takeaways
- NDC 00075-2915 (Zolgensma) is a high-cost, one-time gene therapy for pediatric SMA type 1.
- The US market anticipates annual sales near $330-$350 million, with potential to expand as diagnosis and coverage improve.
- Price stability is expected at approximately $2.1 million per dose, with limited near-term reductions.
- Market expansion and global penetration are core revenue growth drivers.
- Reimbursement environment and competitive dynamics will influence future pricing and market share.
FAQs
1. Is Zolgensma's price justified?
Price justifications center on its curative potential and savings over lifelong therapies, but high upfront costs pose reimbursement challenges.
2. What factors could impact Zolgensma's market share?
Emerging competitors, shifting reimbursement policies, or new clinical data could influence market dynamics.
3. Are there ongoing price reductions or discounts?
Yes, negotiations with payers can lead to discounts of 10-15%, depending on volume and formulary agreements.
4. How does Zolgensma compare to Spinraza and Evrysdi?
Zolgensma offers a single-dose cure, while Spinraza and Evrysdi are administered repeatedly, influencing patient choice and insurer coverage.
5. What is the potential for global market growth?
Significant, especially in Europe and Asia, as regulatory approvals and newborn screening programs expand.
References
- Novartis. (2022). Zolgensma (onasemnogene abeparvovec-xioi) sales report. [Online] Available at: https://www.novartis.com [Accessed: 27 Feb 2023].
- FDA. (2019). Zolgensma approval letter. [Online] Available at: https://www.fda.gov [Accessed: 27 Feb 2023].
- ICER. (2020). Gene therapies for SMA: Cost-effectiveness analysis. [Online] Available at: https://icer.org [Accessed: 27 Feb 2023].
[Note: Additional data sources include market research reports from IQVIA, EvaluatePharma, and industry publications.]
